학술논문

200O Pembrolizumab plus axitinib (pembro + axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern Asia
Document Type
Abstract
Source
In Annals of Oncology November 2020 31 Supplement 6:S1319-S1319
Subject
Language
ISSN
0923-7534